| scholarly article | Q13442814 |
| P2093 | author name string | C. Caron | |
| J. Goudemand | |||
| C. Chopin | |||
| F. Fourrier | |||
| A. Marey | |||
| A. Rime | |||
| P. Lestavel | |||
| S. Hendrycx | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | sepsis | Q183134 |
| disseminated intravascular coagulation | Q823027 | ||
| septic shock | Q1765564 | ||
| P304 | page(s) | 816-823 | |
| P577 | publication date | 1992-03-01 | |
| P1433 | published in | Chest | Q5093377 |
| P1476 | title | Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies | |
| P478 | volume | 101 |
| Q50913810 | 6-Methylsulfinylhexyl isothiocyanate modulates endothelial cell function and suppresses leukocyte adhesion. |
| Q41927869 | A Proposal of the Modification of Japanese Society on Thrombosis and Hemostasis (JSTH) Disseminated Intravascular Coagulation (DIC) Diagnostic Criteria for Sepsis-Associated DIC. |
| Q39250461 | A study of disseminated intravascular coagulation in acute leukemia reveals markedly elevated D-dimer levels are a sensitive indicator of acute promyelocytic leukemia |
| Q88365528 | A summary of the Japan septic disseminated intravascular coagulation study |
| Q40774975 | AT III in septicemia with DIC. |
| Q34135317 | Acquired antithrombin deficiency in sepsis |
| Q33558189 | Activated factor X signaling via protease-activated receptor 2 suppresses pro-inflammatory cytokine production from lipopolysaccharide-stimulated myeloid cells |
| Q36507496 | Activated protein C ameliorates Bacillus anthracis lethal toxin-induced lethal pathogenesis in rats |
| Q42962104 | Activated protein C improves intestinal microcirculation in experimental endotoxaemia in the rat. |
| Q51341186 | Activated protein C: the cure for sepsis - again? |
| Q34749727 | Acute Escherichia coli mastitis in dairy cattle: diagnostic parameters associated with poor prognosis |
| Q64892718 | Advance in the Management of Sepsis-Induced Coagulopathy and Disseminated Intravascular Coagulation. |
| Q35732033 | Advances in sepsis therapy |
| Q37090618 | Advances in understanding sepsis |
| Q36285943 | Animal models of sepsis: setting the stage |
| Q41747279 | Antimicrobial effects of helix D-derived peptides of human antithrombin III |
| Q48020761 | Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study. |
| Q40770250 | Antithrombin III and local serum application: adjuvant therapy in peritonitis |
| Q77169250 | Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis |
| Q58610034 | Antithrombin III prevents 60 min warm intestinal ischemia reperfusion injury in rats |
| Q58763094 | Antithrombin deficiency is associated with mortality and impaired organ function in septic pediatric patients: a retrospective study |
| Q43251273 | Antithrombin in sepsis revisited |
| Q34999422 | Antithrombin supplementation for anticoagulation during continuous hemofiltration in critically ill patients with septic shock: a case-control study |
| Q46576624 | Antithrombotic agents in the treatment of severe sepsis |
| Q28296136 | Assessment of the interplay between blood and skin vascular abnormalities in adult purpura fulminans |
| Q34575766 | Association between plasminogen activator inhibitor-1 -675 4G/5G polymorphism and sepsis: a meta-analysis |
| Q24794238 | Bench-to-bedside review: endothelial cell dysfunction in severe sepsis: a role in organ dysfunction? |
| Q24794692 | Bench-to-bedside review: functional relationships between coagulation and the innate immune response and their respective roles in the pathogenesis of sepsis |
| Q36987136 | Benefit-risk assessment of drotrecogin alfa (activated) in the treatment of sepsis |
| Q37724049 | Blood coagulation disorders in septic patients |
| Q37628848 | Changes in plasma levels of natural anticoagulants in disseminated intravascular coagulation: high prognostic value of antithrombin and protein C in patients with underlying sepsis or severe infection |
| Q44007754 | Characterisation of changes in the haemostasis system in dogs with thrombosis |
| Q35539676 | Clinical Trial Design and Outcomes in Patients with Severe Sepsis |
| Q34577529 | Clinical trials of immunomodulatory therapies in severe sepsis and septic shock |
| Q24796861 | Close relationship of tissue plasminogen activator-plasminogen activator inhibitor-1 complex with multiple organ dysfunction syndrome investigated by means of the artificial pancreas |
| Q39596346 | Coagulation abnormalities in dengue hemorrhagic Fever: serial investigations in 167 Vietnamese children with Dengue shock syndrome |
| Q40774989 | Coagulation disorders in septic shock |
| Q34212373 | Coagulation dysfunction in sepsis and multiple organ system failure |
| Q40990081 | Coagulation inhibitor substitution during sepsis |
| Q43865671 | Combined antithrombin and protein C supplementation in meningococcal purpura fulminans: a pharmacokinetic study |
| Q35042922 | Conclusions: drotrecogin alfa (activated)--from bench to practical use at the bedside |
| Q43986205 | Continuous hemofiltration and platelet function in critically ill patients. |
| Q33409905 | Contribution of protein Z and protein Z-dependent protease inhibitor in generalized Shwartzman reaction |
| Q35126998 | Current Clinical Practice DIC 2002: A Review of Disseminated Intravascular Coagulation |
| Q33502675 | Current drug treatment strategies for disseminated intravascular coagulation |
| Q35146737 | DIC score in pregnant women--a population based modification of the International Society on Thrombosis and Hemostasis score. |
| Q43818054 | Decreased plasma activity of antithrombin or protein C is not due to consumption coagulopathy in septic patients with disseminated intravascular coagulation |
| Q57492154 | Dexamethasone Preconditioning in Cardiac Procedures Reduces Decreased Antithrombin Activity and Is Associated to Beneficial Outcomes: Role of Endothelium |
| Q91867008 | Diagnosis of sepsis-induced disseminated intravascular coagulation and coagulopathy |
| Q47702345 | Disseminated intravascular coagulation in pediatric patients: clinical and laboratory features and prognostic factors influencing the survival. |
| Q34302117 | Disseminated intravascular coagulation: a review for the internist |
| Q40769843 | Disseminated intravascular coagulation: clinical complexities of aberrant coagulation. |
| Q71621653 | Does long-term continuous administration of pentoxifylline affect platelet function in the critically ill patient? |
| Q77762835 | Drotrecogin alfa (activated) |
| Q47910814 | Drotrecogin alfa (activated) in an infant with gram-negative septic shock |
| Q36607385 | Drotrecogin alfa (activated) in the treatment of severe sepsis |
| Q30788622 | Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial |
| Q35059326 | Drotrecogin alfa (activated): a novel therapeutic strategy for severe sepsis |
| Q36981698 | Drotrecogin alpha (activated): the treatment for severe sepsis? |
| Q36295952 | Early and innovative interventions for severe sepsis and septic shock: taking advantage of a window of opportunity |
| Q33497946 | Effect of FR167653, a cytokine suppressive agent, on endotoxin-induced disseminated intravascular coagulation |
| Q39780897 | Efficacy and Bleeding Risk of Antithrombin Supplementation in Patients With Septic Disseminated Intravascular Coagulation: A Third Survey |
| Q35107098 | Efficacy of antithrombin in preclinical and clinical applications for sepsis-associated disseminated intravascular coagulation |
| Q36835719 | Emerging role of anticoagulants and fibrinolytics in the treatment of acute respiratory distress syndrome |
| Q34449865 | Eritoran: the evidence of its therapeutic potential in sepsis |
| Q46099605 | Extended drotrecogin alfa (activated) treatment in patients with prolonged septic shock |
| Q73453315 | FR167653, a dual inhibitor of interleukin-1 and tumor necrosis factor-alpha, ameliorates endotoxin-induced shock |
| Q34528902 | From evidence to clinical practice: effective implementation of therapeutic hypothermia to improve patient outcome after cardiac arrest |
| Q40666343 | Guidance on patient identification and administration of recombinant human activated protein C for the treatment of severe sepsis |
| Q33712746 | Hemostatic Changes Associated With Increased Mortality Rates in Hospitalized Patients With HIV-Associated Tuberculosis: A Prospective Cohort Study |
| Q44627401 | Hemostatic Changes in Dogs with Naturally Occurring Sepsis |
| Q37237490 | Hyperantithrombotic, noncytoprotective Glu149Ala-activated protein C mutant |
| Q47126929 | Immunohaemostasis: a new view on haemostasis during sepsis |
| Q61864352 | In vivo effect of adhesion inhibitor heparin on Legionella pneumophila pathogenesis in a murine pneumonia model |
| Q36538119 | Incidence of pulmonary thromboembolism, infarction and haemorrhage in disseminated intravascular coagulation: a necroscopic analysis |
| Q33740009 | Indications for prothrombin complex concentrates in massive transfusions |
| Q35127410 | Inflammation and Coagulation: Implications for the Septic Patient |
| Q35960658 | Inflammatory Kidney and Liver Tissue Response to Different Hydroxyethylstarch (HES) Preparations in a Rat Model of Early Sepsis |
| Q28083003 | Initial resuscitation and management of pediatric septic shock |
| Q61866663 | Interleukin-10 inhibits endotoxin-induced tissue factor mRNA production by human monocytes |
| Q37341652 | Intracellular and extracellular serpins modulate lung disease |
| Q35042912 | Introduction: rationale for using drotrecogin alfa (activated) in patients with severe sepsis |
| Q35091715 | Is antithrombin treatment of disseminated intravascular coagulation a quixotic goal? |
| Q38117275 | Lack of association between factor V Leiden and sepsis: a meta-analysis |
| Q35196165 | Levels of protein C and soluble thrombomodulin in critically ill patients with acute kidney injury: a multicenter prospective observational study |
| Q73666778 | Low utilisation of unactivated protein C in a patient with meningococcal septic shock and disseminated intravascular coagulation |
| Q38930881 | Low-grade endotoxemia and clotting activation in the early phase of pneumonia |
| Q48516198 | Management of disseminated intravascular coagulation: current insights on antithrombin and thrombomodulin treatments |
| Q36259598 | Microcirculatory alterations in ischemia-reperfusion injury and sepsis: effects of activated protein C and thrombin inhibition |
| Q28365996 | Microvascular endothelial dysfunction: a renewed appreciation of sepsis pathophysiology |
| Q53271857 | Modified score for disseminated intravascular coagulation in the critically ill. |
| Q35737359 | Modulating LPS signal transduction at the LPS receptor complex with synthetic Lipid A analogues |
| Q34661567 | Multiple organ dysfunction syndrome in humans and animals |
| Q38006576 | Nebulized anticoagulants for acute lung injury - a systematic review of preclinical and clinical investigations |
| Q35622651 | New approaches to the treatment of sepsis |
| Q52668975 | Optimal Antithrombin Activity Threshold for Initiating Antithrombin Supplementation in Patients With Sepsis-Induced Disseminated Intravascular Coagulation: A Multicenter Retrospective Observational Study. |
| Q49223126 | Panton-Valentine Leukocidin associated with S. aureus osteomyelitis activates platelets via neutrophil secretion products |
| Q33893328 | Pathogenesis and management of multiple organ dysfunction or failure in severe sepsis and septic shock |
| Q38141738 | Pathophysiologic mechanisms in septic shock |
| Q84464759 | Persistent hypocoagulability in patients with septic shock predicts greater hospital mortality: impact of impaired thrombin generation |
| Q35030573 | Pharmacokinetics and clinical use of drotrecogin alfa (activated) in patients with severe sepsis |
| Q35030570 | Pharmacology, clinical efficacy, and safety of drotrecogin alfa (activated). |
| Q36467694 | Pharmacotherapy of acute lung injury and the acute respiratory distress syndrome |
| Q41948880 | Physiological Levels of Pentraxin 3 and Albumin Attenuate Vascular Endothelial Cell Damage Induced by Histone H3 In Vitro |
| Q44804213 | Physiopathology of severe sepsis |
| Q74382158 | Pig I alpha I appears unmodified in plasma in case of endotoxin-induced disseminated intravascular coagulation |
| Q80672463 | Plasma derived protein C in severe sepsis: report of two cases |
| Q37409613 | Plasma protein C levels in immunocompromised septic patients are significantly lower than immunocompetent septic patients: a prospective cohort study. |
| Q26853685 | Pneumonia, thrombosis and vascular disease |
| Q49091705 | Prediction of survival in patients suspected of disseminated intravascular coagulation |
| Q40791897 | Predictors of fatal outcomes resulting from acute Escherichia coli mastitis in dairy cows |
| Q38640508 | Present and future of anticoagulant therapy using antithrombin and thrombomodulin for sepsis-associated disseminated intravascular coagulation: a perspective from Japan |
| Q43648347 | Pretreatment with peroxysome proliferator-activated receptor alpha agonist fenofibrate protects endothelium in rabbit Escherichia coli endotoxin-induced shock. |
| Q97549066 | Profile of natural anticoagulant, coagulant factor and anti-phospholipid antibody in critically ill COVID-19 patients |
| Q28076449 | Proposal for new diagnostic criteria for DIC from the Japanese Society on Thrombosis and Hemostasis |
| Q40646976 | Protein C and thrombomodulin in human acute lung injury |
| Q81725856 | Protein C as an early marker of severe septic complications in diffuse secondary peritonitis |
| Q42905403 | Protein C concentrations in severe sepsis: an early directional change in plasma levels predicts outcome |
| Q37508524 | Protein C in critical illness |
| Q36749051 | Protein C: a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin alfa (activated) |
| Q35781515 | Proteolytic activity and fatal gram-negative sepsis in burned mice: effect of exogenous proteinase inhibition. |
| Q35344705 | Purification of protein C from canine plasma |
| Q35561206 | Randomized trial evaluating serial protein C levels in severe sepsis patients treated with variable doses of drotrecogin alfa (activated). |
| Q48109327 | Recent advances in pathophysiology of disseminated intravascular coagulation: the role of circulating histones and neutrophil extracellular traps |
| Q34796994 | Recombinant human activated protein C for use in severe sepsis |
| Q34443368 | Recombinant human activated protein C, drotrecogin alfa (activated): a novel therapy for severe sepsis |
| Q43182531 | Reduction of D-dimer levels after therapeutic administration of antithrombin in acquired antithrombin deficiency of severe sepsis. |
| Q33392033 | Relation between coagulation/fibrinolysis and lactate in the course of human septic shock |
| Q73068632 | Relationship between platelet activation and cytokines in systemic inflammatory response syndrome patients with hematological malignancies |
| Q40125387 | Retrospective comparison of thromboelastography results to postmortem evidence of thrombosis in critically ill dogs: 39 cases (2005-2010). |
| Q37258045 | Revision of the Japanese Association for Acute Medicine (JAAM) disseminated intravascular coagulation (DIC) diagnostic criteria using antithrombin activity |
| Q35647766 | Sepsis and disseminated intravascular coagulation |
| Q40540763 | Sepsis and septic shock. II. Treatment. |
| Q36995847 | Sepsis: a clinical update. |
| Q35030565 | Sepsis: a frequent, life-threatening syndrome |
| Q37655890 | Sepsis: multiple abnormalities, heterogeneous responses, and evolving understanding |
| Q33973581 | Several Cytokines and Protein C Levels with the Apache II Scoring System for Evaluation of Patients with Sepsis |
| Q37290652 | Severe congenital protein C deficiency: the use of protein C concentrates (human) as replacement therapy for life-threatening blood-clotting complications |
| Q40099276 | Severe infections and subsequent delayed cardiovascular disease |
| Q35128911 | Such stuff as dreams are made on: mediator-directed therapy in sepsis |
| Q37909137 | Systemic versus localized coagulation activation contributing to organ failure in critically ill patients |
| Q36011334 | Temporal trends in the utilization of vasopressors in intensive care units: an epidemiologic study. |
| Q57527492 | The Management of Sepsis: A Practical Review |
| Q33832002 | The caput medusae of hypercoagulability |
| Q41344164 | The coagulopathy in sepsis: significance and implications for treatment |
| Q34914193 | The diagnosis of disseminated intravascular coagulation. |
| Q81507572 | The effect of fibrinolytic enzyme FIIa from Agkistrodon acutus venom on disseminated intravascular coagulation in rabbits |
| Q48371582 | The effect of sepsis and its inflammatory response on mechanical clot characteristics: a prospective observational study |
| Q34257657 | The loss of homeostasis in hemostasis: new approaches in treating and understanding acute disseminated intravascular coagulation in critically ill patients |
| Q37773794 | The microcirculation in sepsis. |
| Q33751764 | The prognostic value of ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 repeats, member 13) deficiency in septic shock patients involves interleukin-6 and is not dependent on disseminated intravascular coagulation |
| Q37561507 | The protein C pathway and pathologic processes |
| Q37082973 | The protein C pathway: implications for the design of the RESPOND study |
| Q46953002 | The role of protein C in sepsis |
| Q77308915 | The role of the endothelium in changes in procoagulant activity in sepsis |
| Q37852747 | Therapeutic modulation of coagulation and fibrinolysis in acute lung injury and the acute respiratory distress syndrome |
| Q35008797 | Thromboelastometry and organ failure in trauma patients: a prospective cohort study |
| Q42589170 | Thrombomodulin: a bifunctional modulator of inflammation and coagulation in sepsis |
| Q35659166 | Tracheostomy in intensive care unit patients can be performed without bleeding complications in case of normal thromboelastometry results (EXTEM CT) despite increased PT-INR: a prospective pilot study |
| Q30465464 | Transfusion therapy in acquired coagulopathies. |
| Q51955997 | Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. |
| Q44804215 | Treatment of severe sepsis and septic shock |
| Q36026794 | Use of a semiquantitative procalcitonin kit for evaluating severity and predicting mortality in patients with sepsis |
| Q50945162 | Use of drotrecogin alpha (recombinant human activated protein C, rhAPC) in the treatment of severe sepsis induced by graft pancreatitis after simultaneous pancreas and kidney transplantation: a case report. |
| Q43003934 | When acquired thrombophilia mattered |
| Q52951509 | [Coagulation inhibitors in severe sepsis: state of the art]. |
| Q73768763 | [Microcirculation and hemostasis in inflammatory processes. Modulation by administration of physiologic protease inhibitors as a therapeutic approach] |
| Q81581827 | [Role of coagulation in acute pulmonary lesion physiopathology. Parallelism with sepsis] |
| Q77339695 | [The paradox of disseminated intravascular coagulation] |
Search more.